Tekla Capital Management’s Praxis Precision Medicines PRAX Stock Holding History

Tekla Capital Management’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$86.3K	Hold	5,000	–	–	﹤0.01%	159
2023 Q1	$60.7K	Hold	5,000	–	–	﹤0.01%	173
2022 Q4	$179K	Hold	5,000	–	–	0.01%	163
2022 Q3	$170K	Hold	5,000	–	–	0.01%	160
2022 Q2	$184K	Hold	5,000	–	–	0.01%	169
2022 Q1	$766K	Hold	5,000	–	–	0.03%	151
2021 Q4	$1.48M	Hold	5,000	–	–	0.05%	134
2021 Q3	$1.39M	Hold	5,000	–	–	0.04%	144
2021 Q2	$1.37M	Hold	5,000	–	–	0.04%	166
2021 Q1	$2.46M	Hold	5,000	–	–	0.08%	154
2020 Q4	$4.13M	Buy	+5,000	New	+$2.92M	0.15%	128

Other funds holding PRAX

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

TLP

Tri Locum Partners New York $713M AUM 68.92% 1-Year Est. Return

Tekla Capital Management's PRAX Position: Q2 2023 in Review

Tekla Capital Management held its Praxis Precision Medicines (PRAX) position steady in Q2 2023 at 5,000 shares worth $86.3K. The position accounts for ﹤0.01% of the portfolio, ranked #159.

Tekla Capital Management first reported a position in PRAX in Q4 2020 and has held it in 11 quarters since. The position peaked at $4.13M in Q4 2020. 78 funds tracked by Wall St. Rank hold PRAX as of Q2 2023.

Tekla Capital Management held 5,000 shares of Praxis Precision Medicines worth $86.3K as of Q2 2023.
Tekla Capital Management left its Praxis Precision Medicines share count unchanged in Q2 2023.
Praxis Precision Medicines made up ﹤0.01% of Tekla Capital Management's portfolio in Q2 2023, its #159 holding.
Tekla Capital Management first reported a position in Praxis Precision Medicines in Q4 2020 and has held it in 11 quarters since.
Tekla Capital Management's Praxis Precision Medicines position peaked at $4.13M in Q4 2020.
78 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.